Jim Cramer Likes This Stock Over Cassava Sciences And Biogen

Jim Cramer Likes This Stock Over Cassava Sciences And Biogen

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. SAVA is "not the one." He likes Eli Lilly and Co LLY over Cassava Sciences and Biogen Inc. BIIB.

Cramer said Root, Inc. ROOT is a "not-so-great" insurance technology firm. He recommends selling the stock.

The "Mad Money" host said he likes salesforce.com, inc. CRM over Zeta Global Holdings Corp. ZETA: "We can go with the established ones," he added.

Cramer recommends buying Doximity, Inc’s DOCS stock.

ViacomCBS Inc. VIAC is "not expensive at all," Cramer said. He was also intrigued by insider buying in the stock.

Price Action: Shares of Cassava Sciences gained 2% to close at $61.69, while Eli Lilly and Biogen lost 0.3% and 3.8%, respectively on Tuesday.

Root’s stock slipped 0.6%, while salesforce gained 0.5% and Zeta Global dropped 1.5% in the previous session.

Shares of Doximity and ViacomCBS fell 4.2% and 1.8%, respectively.

Posted In: CNBCJim Cramermad money Lightning RoundLong IdeasNewsSmall CapMediaTrading Ideas